Cipla to market MSD’s HIV drug in India
Cipla and MSD on Thursday announced an India specific strategic partnership under which the former will have a non-exclusive licence to market, promote and distribute MSD’s ‘raltegravir’ 400 mg tablet, an HIV drug, under a different brand name. MSD is the trade name of US-based Merck —operates in India through three separate legal entities: MSD Pharmaceuticals, Organon (India), and Fulford (India).
Jubilant arm expands drug find alliance with Janssen
Jubilant Biosys, an arm of Jubilant Life Sciences, on Thursday announced expansion of its drug discovery alliance with Janssen Pharmaceutica into multiple therapeutic areas. The alliance which was forged initially in 2011 to deliver preclinical candidates to Janssen, has been expanded to leverage Jubilant’s drug discovery capabilities on selected drug discovery targets to advance programmes in multiple disease areas, the company said in a statement. “Most of the research will be undertaken at Jubilant Biosys, India and some parts at Jubilant Discovery Centre, USA,” it added.
Cargill to start operating Karnataka unit by June ’15
Diversified group Cargill India will start operating its $100-million mill in Karnataka by June next year, processing about 800 tonnes of locally sourced corn per day, a top official of the company has said. “We expect to start production from June next year. Construction of the mill started recently,” the company’s chairman Siraj Chaudhry said. The mill is based in the heart of corn growing areas of Karnataka.
Shapoorji Pallonji to build a new facility in Dubai
Shapoorji Pallonji has been appointed the main contractor for a new medical centre based in Dubai Healthcare City. The facility, which is being built for the client Dr Sulaiman Al Habib Group, will provide 175,000 sq ft of internal space arranged over six floors. “Having built our first hospital in the UAE in 1980 in Abu Dhabi, we’re proud that over thirty years later we continue to support healthcare in the market with the same diligence,” said MD Saini, CEO (construction division), Shapoorji Pallonji.
Steady rise in casualties at SAIL plants, says Beni
The number of casualties due to fatal accidents such as fall from height, explosion, fire and electrocution